Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. It also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development. Pangaea Oncology, S.A. was founded in 2006 and is based in Barcelona, Spain.
Spanish Market Performance
7D7 Days: -1.0%
3M3 Months: 2.9%
1Y1 Year: 27.9%
YTDYear to Date: 16.7%
Over the last 7 days, the market has remained flat, although notably the Energy sector declined by 5.7%. More promisingly, the market is up 28% over the past year. Looking forward, earnings are forecast to grow by 4.5% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.